This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Seattle Genetics And Agensys, An Affiliate Of Astellas, Announce Co-Development Of An Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration

Seattle Genetics, Inc. (NASDAQ:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), today announced that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies’ existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 1 trial of ASG-15ME.

“Through our collaboration and co-development agreements with companies like Agensys/Astellas, Seattle Genetics continues to enhance its ability to innovate by combining our industry-leading ADC technology with proprietary cancer targets and antibodies to develop potential new treatments for patients with cancer,” said Eric L. Dobmeier, Chief Operating Officer of Seattle Genetics. “ADCs represent a novel therapeutic approach, and through our pipeline and collaborations more than half of the ADC candidates in clinical development utilize our technology. We look forward to working with Agensys/Astellas to advance ASG-15ME.”

“We’re eager to continue our strong collaboration with Seattle Genetics for ASG-15ME,” said David Stover, Ph.D., Senior Vice President, Agensys Site Head. “This collaboration with Seattle Genetics is in line with our goal to utilize the most advanced technologies to generate more innovative medicines in oncology.”

ASG-15ME is an ADC composed of a fully human antibody directed to SLITRK6, an antigen expressed in multiple solid tumors. Preclinically, ASG-15ME has demonstrated antitumor activity in models of bladder and lung cancer. The antibody is attached to a potent, synthetic cytotoxic agent, monomethyl auristatin E (MMAE), via an enzyme-cleavable linker using Seattle Genetics’ proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLITRK6-expressing tumor cells, resulting in targeted cell-killing.

Upon the option exercise, Seattle Genetics will make an option exercise payment and thereafter fund half of the future development costs for the ASG-15ME program. The impact of the option exercise on Astellas’ current fiscal year (from April 1, 2013, to March 31, 2014) financial forecast will be immaterial.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,039.49 +60.36 0.36%
S&P 500 1,992.37 +5.86 0.30%
NASDAQ 4,532.1040 +5.6220 0.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs